More Videos
- Is Merck A Drug Bellwether?
- Pfizer's Statin Study: What A Coincidence!
- Sam Waksal: "Moving On Up" To The East Side
- Another "Short" Story About Pfizer & Dendreon
- Predictions: 9 For '09 In Pharma
- Johnson & Johnson Is Latest FDA Casualty
- Genentech: Roche Says One Thing, Investors Say Another
- Schering-Plough: The Reviews Are In
- Pharma Updates And What You Need To Know
- The Emails Fly On GM, Ford CEO's Corporate Jets
- Cramer to Geithner: Let FDIC Chair Keep Her Job
- Lightning Round: Boeing, Medtronic, Agrium and More
- Lightning Round OT: Continental, Amylin Pharma and More
- Sell Block: Cramer's Solution for Mortgage-Backed Paper Mess
- Toll Brothers CEO's Housing Outlook
- Making Money Off M&A
- Your First Move For Friday December 5th
- Web Extra: Fast & Furious Trades For Friday
- Bear Market Boot Camp, Pt. 2
- Honda Plans to Pull Out of Formula One
- Job Cuts Picking Up Steam Just in Time for Holidays
- Pros Say: Bear Market Rallies = New Reality
- CEOs Sound Off: Budget Deficit, Bailouts & More
- Bernanke: 'More Needs To Be Done' on Foreclosures
- Bernanke's Speech on Housing and Foreclosures
- With Saturn, G.M. Failed a Makeover
- Toll Loss Narrows, but Warns on Revenue
- Factory Orders Drop More Than Expected in October
Text Size 
 |
] are taking another little breather after rising to around 99 bucks on speculation that a higher offer is coming from Roche.
Analyst guestimates of the ultimate takeout price -- if, indeed there is one -- are generally above a hundred dollars a share.
And the guy who recently suggested that $130 isn't out of the question is changing his odds today of a deal getting done.
Geoffrey Porges at Sanford C. Bernstein, who had been lamenting the potential loss of the Genentech culture and machine since Roche made its surprise bid, is now telling clients in a research note that an "acquisition seems inevitable."
He cites the recent statement from the special Genentech board committee, which Porges says "suggests that the company is resigned to a transaction..."
As a result, he's raising his DNA price target from $101 to $109.
But don't expect a deal to get done overnight: Porges thinks there will be at least one or two more negotiating rounds before they come to terms somewhere in the range of $105-$115 a share.
Finally, he now ascribes a less than 15 percent chance of the whole thing falling apart. But if that happens, look out below.
A unit of Bernstein owns at least 1 percent of DNA.
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes